These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 27075128)

  • 41. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis.
    Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ
    J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunomodulatory effects of IFN-beta1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS).
    Pede PD; Visintini D; Telera A; Cucurachi L; Campanini C; Immovilli P; Vescovini R; Sansoni P
    J Interferon Cytokine Res; 2005 Aug; 25(8):485-9. PubMed ID: 16108731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Saccà F; Russo CV; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2018 Jan; 19():50-54. PubMed ID: 29128737
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients.
    Rep MH; Schrijver HM; van Lopik T; Hintzen RQ; Roos MT; Adèr HJ; Polman CH; van Lier RA
    J Neuroimmunol; 1999 Apr; 96(1):92-100. PubMed ID: 10227428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon beta1a treatment modulates TH1 expression in gammadelta + T cells from relapsing-remitting multiple sclerosis patients.
    Elliott CL; El-Touny SY; Filipi ML; Healey KM; Leuschen MP
    J Clin Immunol; 2001 May; 21(3):200-9. PubMed ID: 11403227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T-cell interleukin-6 receptor binding in interferon-beta-1b-treated multiple sclerosis patients.
    Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
    Eur J Neurol; 2000 Nov; 7(6):647-53. PubMed ID: 11136350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Interferon-Beta Treatment on the Proportion of T Helper 17 Cells and Related Cytokines in Multiple Sclerosis: A Meta-Analysis.
    Hou M; Li Y; He L; Li X; Ding Z; Du Y; Zhang Y; Zhang S; Li X
    J Interferon Cytokine Res; 2019 Dec; 39(12):771-779. PubMed ID: 31517556
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS.
    Zang YC; Yang D; Hong J; Tejada-Simon MV; Rivera VM; Zhang JZ
    Neurology; 2000 Aug; 55(3):397-404. PubMed ID: 10932275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
    Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
    Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P; Alm GV; Fredrikson S; Link H
    Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis.
    Zang YC; Skinner SM; Robinson RR; Li S; Rivera VM; Hutton GJ; Zhang JZ
    Mult Scler; 2004 Oct; 10(5):499-506. PubMed ID: 15471364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virus-induced interferon alpha/beta (IFN-alpha/beta) production by T cells and by Th1 and Th2 helper T cell clones: a study of the immunoregulatory actions of IFN-gamma versus IFN-alpha/beta on functions of different T cell populations.
    Klimpel GR; Infante AJ; Patterson J; Hess CB; Asuncion M
    Cell Immunol; 1990 Jul; 128(2):603-18. PubMed ID: 2162739
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis.
    Link J; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H
    Ann Neurol; 1994 Sep; 36(3):379-86. PubMed ID: 8080246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients.
    Lünemann JD; Aktas O; Gniadek P; Zschenderlein R; Zipp F
    Neurology; 2001 Sep; 57(6):1132-4. PubMed ID: 11571354
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis.
    Wang X; Chen M; Wandinger KP; Williams G; Dhib-Jalbut S
    J Immunol; 2000 Jul; 165(1):548-57. PubMed ID: 10861095
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
    Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
    Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Xiao B; Kivisäkk P; Fredrikson S; Link H
    Scand J Immunol; 1999 May; 49(5):554-61. PubMed ID: 10320650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.